Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

William Blair analyst Margaret Kaczor acknowledges that while Edwards Lifesciences’ TAVR growth has potential, more evidence is needed to confirm it will reach the high end of 2025 guidance ...

Edwards Lifesciences Corp Larry Wood; Corporate Vice President - Transcatheter Aortic Valve Replacement; Edwards Lifesciences Corp Greetings, and welcome to the Edwards Lifesciences Corporation fourth ...